SAGE Therapeutics Inc (NASDAQ:SAGE) rallied after the Cambridge, Massachusetts-based company said its postpartum depression treatment has shown promise in a clinical trial. After two weeks of outpatient treatment, patents showed statistically significant improvement on a rating scale for depression, according to Sage. In June, the Food and Drug Administration allowed the company to expedite development of its SAGE-217 treatment.
Shares rallied $39.62, or 41%, to $137.13.
QEP Resources Inc (NYSE:QEP) gained as the Denver-based crude oil and natural gas exploration and production company confirmed that it had received a preliminary proposal from Elliott Management Corp to acquire the company for
Shares surged $2.49, or 41%, to $8.57.
AxoGen Inc (NASDAQ:AXGN) fell after publishing preliminary fourth-quarter revenue of $23.4 million, up 38% from a year earlier but less than the analyst consensus of $24.2 million. The Alachua, Florida-based company develops and markets surgical products for peripheral nerve injuries. AxoGen expects 2018 revenue of $83.9 million, up 39% from the prior year.
Shares declined $4.69, or 22%, to $16.59.
NuVasive Inc (NASDAQ:NUVA) dropped after reporting preliminary fourth-quarter revenue of about $288 million, less than the analyst consensus of $294 million. The San Diego company developer of spine surgery technology expects 2018 revenue of about $1.1 billion, up 7% from the prior year.
The stock decreased $3.94, or 7.9%, to $46.08.
The Russell 2000 index of small-cap stocks advanced 1.9% to 1,407.28 on Monday.